Your research may be critical to the success of your company, but it can also expose your company to risk. If you’re inadvertently working on patented sequences, you could face potential liabilities and licensing fees. There’s no excuse for wasting precious R&D resources on proprietary work produced by your competitors.
The biotechnology sector is fast-moving, meaning that you must be able to filter ever-increasing quantities of business and scientific data. Bioinformaticians and IP professionals alike require up-to-date, accurate information on sequence patent activity to help ensure their R&D strategies are protected and pointed on the right track.
Public databases are one answer, but they often provide obscure, jargon-filled summaries that confuse rather than clarify novel inventions. If you rely on these databases, months of commercial R&D could be rendered useless through delays in obtaining released patent sequence information, and you could lose potential licensing opportunities.
GENESEQ™ contains high quality, easy-to-understand annotated genetic sequences from worldwide patents — an essential tool for any organization that needs to know what’s happening in genomic-based life science discovery.
GENESEQ contains more than 8.8 million patented sequences covering genetic discovery back to 1981. As many as 12,000 new records are added every two weeks, with each record annotated by highly-trained editorial staff.
GENESEQ enables you to search sequence information from around the world in a single database. 41 patent authorities are covered, including WO, US, EP, JP, DE, IN and CN. Foreign patents compose over 20% of the database — and English language titles are provided for each foreign patent.
Patents can appear in GENESEQ years before other sequence databases. With GENESEQ™ FASTAlert, you’ll be notified of new sequences within two weeks of patent publication date, putting you far ahead of the competition and ensuring that your IP professionals will not miss any potential infringements or competitor activities.